Can ICON turn governance repair into renewed momentum for clinical research services?
ICON’s restatement and backlog reset test CRO confidence as pharma sponsors weigh execution risk, trial demand and 2026 recovery signals.
A workers’ comp portal may not sound flashy. For orthopaedic care delays, it could matter
Find out how DMOS Orthopaedic Centers’ new workers’ comp portal could speed referrals, reduce delays and improve injury-care coordination.
Drug discovery has an AI problem. Clicklinks thinks the answer is connection, not just algorithms
Find out how Sanyou Bio’s Clicklinks platform could reshape AI-led drug discovery by linking biotech, CRO, CDMO and preclinical resources.
Can emergency Ebola treatment centers close Africa’s outbreak response gap?
Find out how Samaritan’s Purse’s Ebola treatment deployment in Congo highlights urgent gaps in outbreak readiness and field care.
A rare disease policy shift just landed at the WHO. Could it change hemophilia care worldwide?
Find out how the WHO hemophilia resolution could reshape diagnosis, treatment access, prophylaxis and bleeding disorder care worldwide.
How the PharmAla Biotech Holdings Inc. and Jupiter Neurosciences, Inc. deal reflects changing investor expectations in psychedelics
Explore why the PharmAla and Jupiter Neurosciences licensing deal could reshape investor sentiment around next-generation psychedelic therapeutics.
Can non-viral gene therapies solve the safety problem holding back genetic medicine?
Viral vectors built gene therapy’s first era. Safety, redosing and manufacturing pressure are pushing non-viral platforms into the spotlight.
Why clinical biomarkers face a slow climb before regulators accept them as surrogate endpoints
Biomarkers can speed drug approvals, but weak validation can haunt sponsors. FDA and EMA are tightening the path from signal to endpoint.
Is endometriosis diagnosis finally moving beyond surgery after years of missed symptoms?
Endometriosis testing is escaping the surgery-first era. Saliva, blood and imaging tools now face the harder test: clinical utility.
Are autonomous labs quietly turning biopharma researchers into scientific strategists?
Autonomous labs can run experiments faster. The bigger shift is what happens when biopharma researchers stop executing and start directing.